APB A001
Alternative Names: Ab-612; APB-A-001Latest Information Update: 19 Dec 2022
At a glance
- Originator Kangwon National University
- Developer APITBIO
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Neural cell adhesion molecule L1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Dec 2022 Preclinical trials in Solid tumours in South Korea (Parenteral) prior to December 2022 (ApitBio pipeline, December 2022)
- 27 Jun 2022 Kangwon National University Industry Cooperation Foundation files for patent protection for "Anti-L1CAM antibodies" worldwide
- 16 Apr 2021 APITBIO acquires patent for targeted immune anticancer antibody treatment from Kangwon National University (APITBIO website, December 2022).